A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder
Phase: PHASE3 | Sponsor: Cybin IRL Limited | Compound: Psychedelic
- Status
- recruiting
- Institution
- Cybin IRL Limited
- Start date
- 2024-12-17
- End date
- 2026-09-01
- Registry ID
- NCT06564818
Tracked by the DMT Code Clinical Trials Observatory, an open record of DMT-related clinical research.